Abatacept - Bristol-Myers Squibb
Alternative Names: Abata - Bristol-Myers Squibb; BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SCLatest Information Update: 23 Jul 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Cambridge University Hospitals; Columbia University; National Institute for Health Research; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Hospital, Brest; University Medical Center Freiburg; University Medical Center Groningen; University of Michigan; University of Pittsburgh
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies; Urologics
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
- Registered Graft-versus-host disease
- Phase III COVID 2019 infections; Dermatomyositis; Lupus nephritis; Myositis; Polymyalgia rheumatica; Polymyositis
- Phase II Alopecia areata; Common variable immunodeficiency; Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome; Pulmonary sarcoidosis
- No development reported Ulcerative colitis
- Discontinued Crohn's disease; Inflammation; Multiple sclerosis; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection
Most Recent Events
- 12 Jun 2024 Adverse events and efficacy data from a phase III trial in Myositis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 12 Jun 2024 Efficacy and adverse event data from a phase III trial in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 31 Mar 2024 Boston Children's Hospital completes a phase-II trial in Graft-versus-host disease (Prevention, Combination therapy) in Canada, USA (IV) (NCT01743131)